2023
Neuroimaging-based classification of PTSD using data-driven computational approaches: A multisite big data study from the ENIGMA-PGC PTSD consortium
Zhu X, Kim Y, Ravid O, He X, Suarez-Jimenez B, Zilcha-Mano S, Lazarov A, Lee S, Abdallah C, Angstadt M, Averill C, Baird C, Baugh L, Blackford J, Bomyea J, Bruce S, Bryant R, Cao Z, Choi K, Cisler J, Cotton A, Daniels J, Davenport N, Davidson R, DeBellis M, Dennis E, Densmore M, deRoon-Cassini T, Disner S, Hage W, Etkin A, Fani N, Fercho K, Fitzgerald J, Forster G, Frijling J, Geuze E, Gonenc A, Gordon E, Gruber S, Grupe D, Guenette J, Haswell C, Herringa R, Herzog J, Hofmann D, Hosseini B, Hudson A, Huggins A, Ipser J, Jahanshad N, Jia-Richards M, Jovanovic T, Kaufman M, Kennis M, King A, Kinzel P, Koch S, Koerte I, Koopowitz S, Korgaonkar M, Krystal J, Lanius R, Larson C, Lebois L, Li G, Liberzon I, Lu G, Luo Y, Magnotta V, Manthey A, Maron-Katz A, May G, McLaughlin K, Mueller S, Nawijn L, Nelson S, Neufeld R, Nitschke J, O'Leary E, Olatunji B, Olff M, Peverill M, Phan K, Qi R, Quidé Y, Rektor I, Ressler K, Riha P, Ross M, Rosso I, Salminen L, Sambrook K, Schmahl C, Shenton M, Sheridan M, Shih C, Sicorello M, Sierk A, Simmons A, Simons R, Simons J, Sponheim S, Stein M, Stein D, Stevens J, Straube T, Sun D, Théberge J, Thompson P, Thomopoulos S, van der Wee N, van der Werff S, van Erp T, van Rooij S, van Zuiden M, Varkevisser T, Veltman D, Vermeiren R, Walter H, Wang L, Wang X, Weis C, Winternitz S, Xie H, Zhu Y, Wall M, Neria Y, Morey R. Neuroimaging-based classification of PTSD using data-driven computational approaches: A multisite big data study from the ENIGMA-PGC PTSD consortium. NeuroImage 2023, 283: 120412. PMID: 37858907, PMCID: PMC10842116, DOI: 10.1016/j.neuroimage.2023.120412.Peer-Reviewed Original Research
2017
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Molecular Psychiatry 2017, 23: 824-832. PMID: 28397841, PMCID: PMC5636649, DOI: 10.1038/mp.2017.58.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMGluR5 availabilityPositron emission tomographyKetamine administrationControl groupAspartate glutamate receptor antagonistIntravenous ketamine administrationKetamine-induced reductionMetabotropic glutamatergic receptorsRapid antidepressant effectsGlutamate receptor antagonistsKetamine-induced changesEffects of ketaminePET imaging studiesMechanism of actionGlutamate surgeAntidepressant effectsAntidepressant efficacyAntidepressant responseGlutamatergic receptorsControl subjectsReceptor antagonistHealthy controlsDepressive disorderSustained decrease
2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal Of Clinical Psychiatry 2012, 73: 696-702. PMID: 22697193, DOI: 10.4088/jcp.11m07070.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsComparative Effectiveness ResearchCost-Benefit AnalysisDelayed-Action PreparationsDouble-Blind MethodDrug CostsFemaleHealth Care CostsHospitalizationHumansInjectionsKaplan-Meier EstimateMaleMiddle AgedModels, EconometricPsychotic DisordersRisperidoneSchizophreniaUnited StatesVeteransConceptsTotal health care costsHealth care costsLAI risperidoneMedication costsControl groupCare costsVeterans Health Administration patientsHealth care utilizationHealth Related QualityStructured Clinical InterviewUS Medicaid programCase report formsMultisite clinical trialQuality of WellExperimental groupOral antipsychoticsAdverse eventsCare utilizationInjectable risperidoneOutpatient costsHospitalization costsClinical trialsRelated qualityLAI groupPhysician's choice
2005
Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo
Bressan RA, Erlandsson K, Stone JM, Mulligan RS, Krystal JH, Ell PJ, Pilowsky LS. Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo. Biological Psychiatry 2005, 58: 41-46. PMID: 15992521, DOI: 10.1016/j.biopsych.2005.03.016.Peer-Reviewed Original ResearchConceptsHealthy control subjectsTypical antipsychoticsControl subjectsN-methyl-D-aspartate receptor functionN-methyl-D-aspartate receptorsAntipsychotic drug discoveryChronic antipsychotic treatmentDrug-free patientsImpact of schizophreniaNMDA receptor activityHealthy normal volunteersClozapine treatmentAntipsychotic treatmentGlutamatergic systemPatient groupAntipsychotic drugsNonsignificant reductionNMDA receptorsNormal volunteersSchizophrenia patientsControl groupReceptor activityBrain regionsReceptor functionTomography radiotracer
1996
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 9235-9240. PMID: 8799184, PMCID: PMC38625, DOI: 10.1073/pnas.93.17.9235.Peer-Reviewed Original ResearchConceptsAmphetamine-induced dopamine releaseDopamine releaseDopaminergic transmissionPsychotic symptomsSchizophrenic groupDopamine D2 receptor availabilityAmphetamine-induced decreaseAmphetamine-induced reductionD2 receptor availabilityD2 receptor radiotracerPositive psychotic symptomsSingle photon emissionExaggerated stimulationAbnormal responsivenessDopaminergic neuronsHealthy controlsReceptor radiotracerSchizophrenic patientsDopamine hypothesisDopamine functionReceptor availabilityAmphetamine effectsControl groupSchizophrenic subjectsSchizophrenia
1992
Startle gating deficits occur across prepulse intensities in schizophrenic patients
Grillon C, Ameli R, Charney D, Krystal J, Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biological Psychiatry 1992, 32: 939-943. PMID: 1467378, DOI: 10.1016/0006-3223(92)90183-z.Peer-Reviewed Original ResearchConceptsPrepulse inhibitionPrepulse stimulusSchizophrenic patientsStartle reflexControl groupStartle gating deficitsCentral inhibitory mechanismsDeficient prepulse inhibitionGating deficitsStartling stimulusNormal controlsPatientsReflexPrepulse intensityInhibitory mechanismFurther studiesStimuliInhibitionGroup
1991
NO Association Between an Allele at the D2 Dopamine Receptor Gene (DRD2) and Alcoholism
Gelernter J, O'Malley S, Risch N, Kranzler HR, Krystal J, Merikangas K, Kennedy JL, Kidd KK. NO Association Between an Allele at the D2 Dopamine Receptor Gene (DRD2) and Alcoholism. JAMA 1991, 266: 1801-1807. PMID: 1832467, DOI: 10.1001/jama.1991.03470130081033.Peer-Reviewed Original ResearchConceptsControl groupA1 allelePopulation control groupPhysical withdrawal symptomsRandom population controlsSignificant differencesAge of onsetRecent alcohol consumptionAllele frequenciesD2 dopamine receptor geneAntisocial personality disorderWithdrawal symptomsFamily historyAlcoholic subjectsDirect structured interviewsGroup overallAllelic associationDopamine receptor geneAlcohol consumptionAlcohol dependenceControl populationPositive allelic associationAlcoholismPersonality disorderWhite individuals